Patients with Cystic Fibrosis (CF) develop chronic airway infections with the opportunistic gram negative bacteria Pseudomonas aeruginosa. Airway inflammation and neutrophilic infiltration without bacterial destruction characterize these infections. It has been shown that Pseudomonas isolated from Cystic Fibrosis patients have specific, virulence-associated modifications in their lipid A structure. These modifications, which include substitutions with palmitate and 4-aminoarabinose, are responsible for resistance to cationic antimicrobial peptides (CAMPs), an important component of innate immunity and Polymyxin, a CAMP antibiotic. The enzymes responsible for the biosynthesis of 4- aminoarabinose-lipid A are clustered in an operon recently renamed to ArnBCADTEF. Mutation of any of these genes abolishes 4-aminoarabinose addition to lipid A and resistance to CAMPs. Based on our previous structural and biochemical work with ArnA we have developed a strategy for selective inhibition ArnA . In this proposal we also target ArnD, a hypothetical deformylase essential for the biosynthesis of 4- aminoarabinose-lipid A, for biochemical and structural characterization. Inhibition of any of these enzymes would abolish Pseudomonas aeruginosa resistance to antimicrobial peptides, therefore greatly enhancing the host immune response against chronic infections with Pseudomonas. To improve both the quality of life and the survival age of CF patients it is crucial that new strategies are developed to manage their pulmonary infections. Given the chronic nature of these infections preventing or abolishing resistance is a fundamental problem. This proposal focuses on the characterization of bacterial targets that mediate resistance to CAMPs.

Public Health Relevance

Cationic Antimicrobial Peptides (CAMPs) constitute a conserved branch of the innate immune system and is thus one of the first lines of defense against bacterial infections. Several clinical antibiotics, such as colistin and other polymyxins, also belong to this class of molecules. Gram-negative bacteria have evolved a mechanism to chemically modify their envelope and resist killing by this class of antimicrobials. This proposal is focused on understanding the molecular basis of the resistance mechanism and develop strategies to defeat it. Inhibitors of the resistance mechanism would render the bacteria sensitive to CAMPs of the host immune system as well as antibiotics of the same family.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56AI060841-06
Application #
7846396
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Korpela, Jukka K
Project Start
2004-07-01
Project End
2011-06-30
Budget Start
2009-07-17
Budget End
2011-06-30
Support Year
6
Fiscal Year
2009
Total Cost
$368,394
Indirect Cost
Name
University of Colorado at Boulder
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
007431505
City
Boulder
State
CO
Country
United States
Zip Code
80309
Doerner, Pamela Arden; Sousa, Marcelo C (2017) Extreme Dynamics in the BamA ?-Barrel Seam. Biochemistry 56:3142-3149
Lee, Myeongseon; Sousa, Marcelo C (2014) Structural basis for substrate specificity in ArnB. A key enzyme in the polymyxin resistance pathway of Gram-negative bacteria. Biochemistry 53:796-805